Meanwhile GSK3 inhibitors reduce the phosphorylation and degradation of c-Maf in multiple myeloma cells but also reduce the inherent oncogenicity of c-Maf, as they reduce proliferation of the cells [88]. The gene discussed is MAF; the disease is plasma cell myeloma.